Parker Institute

Cancer is on the rise among younger adults, especially women, and is challenging how we think about screening, treatment, and survivorship.

In @HLTHEVENT's The Pulse, Parker Institute CEO @DrKarenKnudsen shares why this rise demands a new approach, from personalized screening and earlier detection to therapeutic cancer vaccines and better support for patients.

Thank you to @MikhailAlexa for highlighting this important conversation.

Read the full story: hlth.com/insights/artic…

Parker Institute is heading to #SITC2026! Parker leaders, investigators, and collaborators will contribute to 32 presentations, posters, and sessions, showcasing the latest advances in cancer vaccines, cell therapies, and immunotherapy.

Congratulations to Catherine J. Wu, MD, Parker Institute Co-Director at @DanaFarber Cancer Institute, on receiving @sitcancer's 2026 Richard V. Smalley Memorial Award and Lectureship!

Explore what the Parker Institute network will be presenting: parkerici.org/news/parker-in…

This #BreastCancerAwarenessMonth, we’re highlighting research focused on one of the biggest challenges in breast cancer: preventing metastasis.

PICI researcher @JudithAgudo1, and the team at @DanaFarber found that spreading triple-negative breast cancer cells activate the glucocorticoid receptor to evade immunity. In preclinical models, combining mifepristone with anti-PD-1 immunotherapy reduced metastatic seeding and extended survival.

Read the study in Nature: nature.com/articles/s4158…

Personalized cancer vaccines are opening new possibilities for cancer treatment, with research exploring how they could prevent recurrence and potentially prevent cancer before it develops.

@nytimes @AgrawalNina highlights the growing momentum behind cancer vaccine research, including the work of Parker Institute researchers Dr. Robert Vonderheide at @PennCancer and Dr. Catherine Wu and Dr. Patrick Ott at @DanaFarber Cancer Institute.

Read more about the Parker researchers advancing cancer vaccine research: nytimes.com/2026/10/23/wel…

This #BreastCancerAwarenessMonth, we’re highlighting work from PICI researcher Robert Vonderheide, MD, PhD, and his team at @PennCancer.

The team used RAS inhibitors on precancerous lesions, nearly doubling survival vs. later treatment in mice. The team is now exploring how this “cancer interception” approach could be combined with immunotherapies, vaccines and other targeted treatments, including in models of precancerous ER+ breast cancer.

Read more: pennmedicine.org/news/new-strat…